Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era.
Jeremie ZerbitMarion DetroitAntoine MeyerJustine DecroocqBenedicte DeauPaul DeschampsRudy BirsenJohanna MondesirPatricia FranchiElsa MiekoutimaCorinne GuerinRui BatistaDidier BouscaryLise WillemsMarguerite VignonPublished in: Viruses (2022)
In the immunocompromised population of patients with hematological malignancies, the underlying treatment of blood cancer by immunotherapy appears to be a risk factor for SARS-CoV-2 infection and for developing a severe form.